Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Androderm (Testosterone Patch)

The transdermal patch that gels displaced

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
FDA Approved (Androderm)

Reference only. Not medical advice.

What can go wrong

Application-site dermatitis is common and the main reason for discontinuation. Patch adhesion and visibility issues.

This is something to take to a clinician. The Atlas can tell you what is known about androderm (testosterone patch) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Androderm is a nightly transdermal testosterone patch. It delivers steady levels and (unlike gels) has no skin-to-skin transference risk, but it is limited by a high rate of application-site skin irritation and the visible patch, which is why gels largely displaced it after 2000. It remains a niche option for men who want transdermal delivery without transference concerns.

Steady levels, but a high rate of skin irritation.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Transdermal TRT without transference

Safety in detail

Requires physician oversight and monitoring.

What it does to fertility

Suppresses spermatogenesis; not fertility-preserving.

What has to be monitored

The bloodwork this needs, and the reason it belongs with a clinician rather than a website.

  • Total testosterone
  • Hematocrit
  • PSA (over 40)

What people get wrong

  • Often saidThe patch is obsolete

    ActuallyIt is niche, not obsolete: for men wanting transdermal delivery without gel transference risk, the patch still has a role despite skin irritation.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

At a glance

Route
Nightly patch
Advantage
No transference (vs gels)
Limitation
Frequent skin irritation

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Androderm (Testosterone Patch). A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.